Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease

Ähnliche Einträge

• Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis
  von: Alex E. Henney, et al.
  Veröffentlicht: (2024)
• Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
  von: Alex E. Henney, et al.
  Veröffentlicht: (2024)
• Real‐world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement
  von: Sahana Mahesh, et al.
  Veröffentlicht: (2025)
• Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study
  von: Jaycie Koh, et al.
  Veröffentlicht: (2024)
• Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
  von: Yu Peng, et al.
  Veröffentlicht: (2025)